New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - daunorubicin hydrochloride 2.14 mg/ml equivalent to daunorubicin 2 mg/ml - solution for injection - 2 mg/ml - active: daunorubicin hydrochloride 2.14 mg/ml equivalent to daunorubicin 2 mg/ml excipient: sodium chloride water for injection - daunorubicin injection is indicated for the treatment of the following: · acute lymphocytic (lymphoblastic) leukaemia: daunorubicin is usually reserved for use in cases shown to be resistant to other drugs. however, combined treatment with daunorubicin, vincristine and a steroid has been used in the early stages of this disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - mitoxantrone hydrochloride 2.3284 mg/ml equivalent to mitoxantrone 2 mg/ml. australian approved name is mitozantrone hydrochloride. - solution for injection - 2 mg/ml - active: mitoxantrone hydrochloride 2.3284 mg/ml equivalent to mitoxantrone 2 mg/ml. australian approved name is mitozantrone hydrochloride. excipient: glacial acetic acid hydrochloric acid nitrogen sodium acetate sodium chloride sodium sulfate water for injection - mitozantrone ebewe is indicated for the treatment of: · metastatic carcinoma of the breast · non-hodgkin's lymphoma · adult acute non-lymphocytic leukaemia (anll) · chronic myelogenous leukaemia in blast crisis

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - daunorubicin, quantity: 20 mg - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - indications as at 22 november 2004 : daunorubicin injection is indicated for the treatment of the following: acute lymphocytic (lymphoblastic) leukaemia: daunorubicin is usually reserved for use in cases shown to be resistant to other drugs. however, combined treatment with daunorubicin, vincristine and a steroid has been used in the early stages of this disease. acute myeloblastic leukaemia: daunorubicin has been used in all stages, alone or in combination with other cytotoxic agents (e.g. cytarabine). disseminated solid tumours: daunorubicin has been investigated for use in these tumours and found to be effective in some cases of disseminated neuroblastoma and rhabdomyosarcoma.

Ireland - English - HPRA (Health Products Regulatory Authority)

claris lifesciences (uk) limited - ondansetron hydrochloride dihydrate - solution for injection - 2 mg/ml - serotonin (5ht3) antagonists

Malta - English - Medicines Authority

pinewood laboratories limited ballymacarbry, clonmel, co. tipperary, ireland - ondansetron hydrochloride, dihydrate - solution for injection/infusion - ondansetron hydrochloride dihydrate 2 mg/ml - antiemetics and antinauseants

Malta - English - Medicines Authority

pinewood laboratories limited ballymacarbry, clonmel, co. tipperary, ireland - ondansetron hydrochloride, dihydrate - solution for injection/infusion - ondansetron hydrochloride dihydrate 2 mg/ml - antiemetics and antinauseants

United States - English - NLM (National Library of Medicine)

teva parenteral medicines, inc. - daunorubicin hydrochloride (unii: ud984i04lz) (daunorubicin - unii:zs7284e0zp) - daunorubicin 5 mg in 1 ml - daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. daunorubicin hydrochloride is contraindicated in patients who have shown a hypersensitivity to it.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - mitozantrone hydrochloride, quantity: 2.328 mg/ml (equivalent: mitozantrone, qty 2 mg/ml) - injection, concentrated - excipient ingredients: sodium chloride; glacial acetic acid; sodium acetate; water for injections - for the treament of: *locally advanced or metastatic carcinoma of the breast *non-hodgkin's lymphoma *adult acute non-lymphocytic leukaemia (anll) *chronic myelogenous leukaemia in blast crisis.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - mitozantrone hydrochloride, quantity: 2.328 mg/ml (equivalent: mitozantrone, qty 2 mg/ml) - injection, concentrated - excipient ingredients: sodium chloride; glacial acetic acid; sodium acetate; water for injections - for the treatment of: *locally advanced or metastatic carcinoma of the breast *non-hodgkin's lymphoma *adult acute non-lymphocytic leukaemia (anll) *chronic myelogenous leukaemia in blast crisis.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - mitozantrone hydrochloride, quantity: 2.328 mg/ml (equivalent: mitozantrone, qty 2 mg/ml) - injection, concentrated - excipient ingredients: sodium chloride; glacial acetic acid; sodium acetate; water for injections - for the treament of: *locally advanced or metastatic carcinoma of the breast *non-hodgkin's lymphoma *adult actue non-lymphocytic leukaemia (anll) *chronic myelogenous leukaemia in blast crisis.